Go Morocco Forums

Khalil

DUBLIN--(BUSINESS WIRE)--Research and Markets (Morocco Pharmaceuticals and Healthcare Report Q2 2009 - Market Research Reports - Research and Markets) has announced the addition of the "Morocco Pharmaceuticals and Healthcare Report Q2 2009" report to their offering.

Morocco Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Morocco's pharmaceuticals and ealthcare industry.

For this Q209 Morocco Pharmaceuticals and Healthcare Report, BMI has forecast the total drug market will increase in value from US$1.38bn in 2008 to US$1.74bn by 2013, representing a compound annual growth rate of 4.75% in US dollar terms. The prescription pharmaceuticals will fall to reach 63.9% proportion of the total drug market by 2013, while over-the counter medicines will increase to a comprise 36.1% by this time.

BMI expects growth to be driven by increased government spending and a growing middle class preferentially self-medicating in skin care (dermatological products). Meanwhile, non-communicable disease will rise through to 2030, posing a higher burden on the healthcare services. Maternal care will remain an urgent issue for the government to address; however, major reforms to fully address this in line with the Millennium Development Goals are still pending.

The health minister of Morocco revealed that MAD428mn (US$49.8mn) was allocated to purchasing medicines in 2008, US$27.8mn more than in 2006. Part of the reason for the increase is due to findings that emergency services are suffering from inadequate distribution and storage of drugs. Medicine management strategies have been outlined, which, if implemented, could vastly improve the access to drugs for public sector health.

Morocco's medical device market was worth MAD1.39bn (US$180mn) in 2008. Like its pharmaceutical market, the medical device market should offer strong growth prospects over the next five years, representing a compound annual growth rate of 11.3% in US dollar terms.

Following several years of strong government expenditure on healthcare infrastructure, BMI expects the capital investment to pay off, and, accordingly, we project that medical device expenditure will accelerate over the forecast period to reach MAD2.70bn (US$307mn) by the end of 2013.

Key Topics Covered:

* Executive Summary
* SWOT Analysis
* Morocco Pharmaceuticals And Healthcare Industry SWOT
* Pharmaceutical Business Environment Ratings
* Risks To Realisation Of Returns
* Market Summary
* Regulatory Regime
* Intellectual Property
* Pricing and Reimbursement Regime
* Regional Regulatory Developments
* Industry Developments .
* Epidemiology
* Healthcare Sector
* Healthcare Reforms
* Health Insurance
* Pharmaceutical Sector
* Pharmaceutical Distribution
* Research & Development
* Industry Forecast Scenario
* Overall Market Forecasts
* Key Growth Factors - Industry
* Economic Activity
* Prescription Drug Market Forecast
* Patented Drug Market Forecast
* Generic Drug Market Forecast
* OTC Drug Market Forecast
* Medical Device Market Forecast
* Pharmaceutical Export/Import Forecasts
* Other Healthcare Data Forecasts
* Key Risks To BMI's Forecasts
* Competitive Landscape
* Company Profiles
* Country Snapshot: Morocco Demographic Data
* Section 1: Population
* Section 2: Education and Healthcare
* Section 3: Labour Market and Spending Power
* BMI Forecast Modelling
* Ratings Overview
* Weighting

Companies Mentioned:

* Sanofi-Aventis
* Pfizer
* GlaxoSmithKline
* Sothema
* Laprophan
* Promopharm

For more information visit Morocco Pharmaceuticals and Healthcare Report Q2 2009 - Market Research Reports - Research and Markets.

Contact:

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716